Angiogenic Biomarkers in Children with Congenital Heart Disease: Possible Implications

Overview

Journal Ital J Pediatr

Publisher Biomed Central

Specialty Pediatrics

Date 2010 Apr 22

PMID 20406482

Citations 5

Authors

Nagla T El-Melegy

Nagwa A Mohamed

Affiliations

Soon will be listed here.

Abstract

Background: Vascular endothelial growth factor (VEGF), platelet derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) and leptin are known as potent angiogenic factors The objective of the study was to evaluate these angiogenic factors VEGF, PD-ECGF/TP and leptin in children with congenital heart disease (CHD) and the factors that lead to angiogenesis in such cases.

Methods: Sixty CHD children were studied and divided into two groups (n=30); cyanotic-CHD (C-CHD) and acyanotic-CHD (A-CHD). Twenty five healthy children were included as controls.

Results: Significantly higher serum levels of VEGF, PD-ECGF/TP activity and leptin were detected in patients with CHD, particularly in patients with C-CHD. CHD patients with SpO2<90%, pulmonary hypertension (PH), severe pulmonary stenosis (PS), detectable collaterals, cardiomegaly and/or heart failure showed significantly higher levels of these factors than those with higher SpO2 or those without these findings.

Conclusion: Hypoxia, PH and PS are important factors that lead to harmful angiogenesis. However, angiogenesis could be essential in some cases of CHD as coarctation of aorta to enhance renal perfusion. This may provide new ways for therapeutic strategies aiming at reducing or promoting angiogenesis in CHD to improve patient's outcome.

Citing Articles

Comparison of CIMT and FMD in the Brachial Artery between Children with Acyanotic Congenital Heart Disease and Healthy Controls: A Case-Control Study.

Ahmadi A, Ghaderian M, Nourmohammadi H, Sabri M, Dehghan B, Mahdavi C J Tehran Heart Cent. 2024; 18(4):256-260.

PMID: 38680641 PMC: 11053238. DOI: 10.18502/jthc.v18i4.14824.

Role of Vascular Endothelial Growth Factor as a Potential Biomarker in Congenital Heart Defects: A Systematic Review.

Ashiq S, Hyder S, Ashiq K, Sabar M J Tehran Heart Cent. 2024; 18(4):237-243.

PMID: 38680637 PMC: 11053233. DOI: 10.18502/jthc.v18i4.14822.

Cerebral oxygen saturation and cerebrovascular instability in newborn infants with congenital heart disease compared to healthy controls.

Tran N, Votava-Smith J, Wood J, Panigrahy A, Wee C, Borzage M PLoS One. 2021; 16(5):e0251255.

PMID: 33970937 PMC: 8109808. DOI: 10.1371/journal.pone.0251255.

Leptin in pediatrics: A hormone from adipocyte that wheels several functions in children.

Soliman A, Yasin M, Kassem A Indian J Endocrinol Metab. 2013; 16(Suppl 3):S577-87.

PMID: 23565493 PMC: 3602987. DOI: 10.4103/2230-8210.105575.

Delineating the angiogenic gene expression profile before pulmonary vascular remodeling in a lamb model of congenital heart disease.

Tian J, Fratz S, Hou Y, Lu Q, Gorlach A, Hess J Physiol Genomics. 2010; 43(2):87-98.

PMID: 20978110 PMC: 3026563. DOI: 10.1152/physiolgenomics.00135.2010.

References

Griffiths L, Dachs G, Bicknell R, Harris A, Stratford I . The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res. 1997; 57(4):570-2. View

Mata-Greenwood E, Meyrick B, Soifer S, Fineman J, Black S . Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2003; 285(1):L222-31. DOI: 10.1152/ajplung.00388.2002. View

Sengupta S, Sellers L, Matheson H, Fan T . Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. Br J Pharmacol. 2003; 139(2):219-31. PMC: 1573835. DOI: 10.1038/sj.bjp.0705216. View

Brown N, Jones A, Fujiyama C, Harris A, Bicknell R . Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 2000; 60(22):6298-302. View

Cao Y . Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007; 117(9):2362-8. PMC: 1963348. DOI: 10.1172/JCI32239. View

Griffioen A, Molema G . Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000; 52(2):237-68. View

Qing M, Quing M, Gorlach A, Schumacher K, Woltje M, Vazquez-Jimenez J . The hypoxia-inducible factor HIF-1 promotes intramyocardial expression of VEGF in infants with congenital cardiac defects. Basic Res Cardiol. 2007; 102(3):224-32. DOI: 10.1007/s00395-007-0639-2. View

Considine R, Sinha M, Heiman M, Kriauciunas A, STEPHENS T, Nyce M . Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334(5):292-5. DOI: 10.1056/NEJM199602013340503. View

Hallioglu O, Alehan D, Kandemir N . Plasma leptin levels in children with cyanotic and acyanotic congenital heart disease and correlations with growth parameters. Int J Cardiol. 2003; 92(1):93-7. DOI: 10.1016/s0167-5273(03)00044-5. View

10.

He H, Venema V, Gu X, Venema R, Marrero M, Caldwell R . Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem. 1999; 274(35):25130-5. DOI: 10.1074/jbc.274.35.25130. View

11.

Mathew R, Gewitz M . Pulmonary hypertension in infancy and childhood. Heart Dis. 2001; 2(5):362-8. View

12.

SCOCCA J . Pyrimidine nucleoside phosphorylase from Haemophilus influenzae. Methods Enzymol. 1978; 51:432-7. DOI: 10.1016/s0076-6879(78)51059-8. View

13.

Li W, Tanaka K, Ihaya A, Fujibayashi Y, Takamatsu S, Morioka K . Gene therapy for chronic myocardial ischemia using platelet-derived endothelial cell growth factor in dogs. Am J Physiol Heart Circ Physiol. 2004; 288(1):H408-15. DOI: 10.1152/ajpheart.00176.2004. View

14.

Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y . Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci U S A. 2001; 98(11):6390-5. PMC: 33478. DOI: 10.1073/pnas.101564798. View

15.

Ray L, Mathieu M, Jespers P, Hadad I, Mahmoudabady M, Pensis A . Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure. Exp Physiol. 2007; 93(3):434-42. DOI: 10.1113/expphysiol.2007.040469. View

16.

Starnes S, Duncan B, Kneebone J, Rosenthal G, Jones T, Grifka R . Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease. J Thorac Cardiovasc Surg. 2000; 119(3):534-9. DOI: 10.1016/s0022-5223(00)70133-4. View

17.

Izumiya Y, Shiojima I, Sato K, Sawyer D, Colucci W, Walsh K . Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 2006; 47(5):887-93. PMC: 3132898. DOI: 10.1161/01.HYP.0000215207.54689.31. View

18.

Fruhbeck G . Intracellular signalling pathways activated by leptin. Biochem J. 2005; 393(Pt 1):7-20. PMC: 1383660. DOI: 10.1042/BJ20051578. View

19.

Felmeden D, Blann A, Lip G . Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J. 2003; 24(7):586-603. DOI: 10.1016/s0195-668x(02)00635-8. View

20.

Hu J, Sun P, Ruan X, Chao A, Lin Y, Li X . Mechanism of myocardial microvessel formation in cyanotic congenital heart disease. Circ J. 2005; 69(9):1089-93. DOI: 10.1253/circj.69.1089. View